Table 1

Baseline demographic and clinical characteristics of patients in intention to treat population. Values are numbers (percentages) unless stated otherwise

CharacteristicsSOC plus HCQ (n=75)SOC (n=75)Total (n=150)
Mean (SD) age, years48.0 (14.1)44.1 (15.0)46.1 (14.7)
Male sex42 (56)40 (53)82 (55)
Mean (SD) body mass index*23.9 (3.24) (n=74)23.2 (3.0) (n=71)23.5 (3.2) (n=145)
Mean (SD) days from disease onset to randomisation16.0 (9.9) (n=73)17.1 (11.1) (n=74)16.6 (10.5) (n=147)
Exposure history:
 Hubei province exposure50/72 (69)53/71 (75)103/143 (72)
 Contact with patients with confirmed covid-1939/72 (54)32/71 (45)71/143 (50)
 Others1/72 (1)1/71 (1)2/143 (1)
 No exposure2/72 (3)9/71 (13)11/143 (8)
 Unknown5/72 (7)5/71 (7)10/143 (7)
Drug treatment before randomisation:47 (63)43 (57.3)90 (60)
 Antiviral agents28 (37)24 (32.0)52 (35)
 Arbidol12 (16)8 (11)20 (13)
 Lopinavir-ritonavir18 (24)14 (19)32 (21)
 Oseltamivir3 (4)3 (4)6 (4)
 Entecavir1 (1)01 (1)
 Virazole3 (4)6 (8)9 (6)
 Ganciclovir02 (3)2 (1)
Disease severity:
 Mild15 (20)7 (9)22 (15)
 Moderate59 (79)67 (89)126 (84)
 Severe1 (1)1 (1)2 (1)
Coexisting conditions:28 (37)17 (23)45 (30)
 Diabetes12 (16)9 (12)21 (14)
 Hypertension6 (8)3 (4)9 (6)
 Others21 (28)10 (13)31 (21)
Vital signs—mean (SD):
 Body temperature, °C36.9 (0.47) (n=72)36.8 (0.48) (n=75)36.8 (0.5) (n=147)
 Pulse, beats/min82.75 (8.0) (n=73)82.5 (9.4) (n=71)82.6 (8.7) (n=144)
 Respiratory rate, breaths/min19.6 (1.3) (n=73)19.7 (1.7) (n=70)19.6 (1.5) (n=143)
 Systolic blood pressure, mm Hg126.3 (13.2) (n=70)123.5 (11.2) (n=69)124.9 (12.3) (n=139)
 Diastolic blood pressure, mm Hg79.1 (8.5) (n=70)76.8 (8.0) (n=69)77.9 (8.3) (n=139)
 Pulse oximetry, %97.4 (1.6)97.3 (1.6) (n=73)97.4 (1.6) (n=148)
Symptoms:
 Fever43/72 (60)40 (53)83/157 (53)
 Cough35/68 (51)26/68 (38)61/136 (45)
 Sputum production11/68 (16)4/68 (6)15/136 (11)
 Shortness of breath15/68 (22)4/68 (6)19/136 (14)
 Nasal congestion000
 Pharynx discomfort2/68 (3)4/68 (6)6/136 (4)
 Fatigue5/68 (7)1/68 (1)6/136 (4)
Laboratory parameters—mean (SD):
 White cell count, ×109/L5.59 (1.9)5.6 (1.8)5.6 (1.8)
 Lymphocyte count, ×109/L1.46 (0.6)1.6 (0.5)1.5 (0.57)
 Neutrophil count, ×109/L3.55 (1.6)4.2 (6.2)3.9 (4.51)
 Platelet count, ×109/L214.8 (68.1)211.7 (71.6)213.2 (69.7)
 Haemoglobin, g/L128.8 (17.5)129.1 (17.1)129.0 (17.3)
 Aspartate aminotransferase, U/L25.0 (13.5)26 (14.7)25.5 (14.1)
 Alanine aminotransferase, U/L31.4 (26.3)32.7 (25.2) (n=74)32.1 (25.7) (n=149)
 γ-glutamyl transpeptidase. U/L46.9 (61.8) (n=73)44.0 (51.8) (n=73)45.4 (56.9) (n=146)
 Total bilirubin, μmol/L11.6 (8.4) (n=74)12.8 (7.7) (n=73)12.2 (8.1) (n=147)
 Albumin, g/L39.9 (4.5) (n=74)40.4 (4.4) (n=74)40.1 (4.4) (n=148)
 Lactate dehydrogenase, U/L203.9 (65.2) (n=66)190.9 (49.5) (n=67)197.4 (58.0) (n=133)
 Creatine kinase, U/L74.4 (110.1) (n=67)71.0 (52.6) (n=68)72.7 (85.7) (n=135)
 Creatine kinase isoenzyme-MB, U/L8.0 (4.2) (n=46)6.8 (3.9) (n=44)7.4 (4.0) (n=90)
 Creatinine, μmol/L71.2 (38.4) (n=74)63.9 (16.0) (n=74)67.5 (29.5) (n=148)
 Blood urea nitrogen, mmol/L3.5 (1.0) (n=44)3.1 (0.7) (n=39)3.3 (0.9) (n=83)
 Urea, mmol/L4.0 (3.0) (n=31)3.8 (1.2) (n=32)4.0 (2.2) (n=63)
 International normalised ratio1.0 (0.1) (n=73)1.0 (0.1) (n=74)1.0 (0.1) (n=147)
 C reactive protein, mg/L9.9 (13.3) (n=73)7.4 (12.8) (n=74)8.6 (13.1) (n=147)
 Erythrocyte sedimentation rate, mm/h30.6 (28.6) (n=72)25.4 (21.7) (n=71)28.0 (25.4) (n=143)
 Tumour necrosis factor α, pg/mL4.9 (4.1) (n=7)4.8 (3.6) (n=7)4.8 (3.7) (n=14)
 Interleukin 6, pg/mL12.9 (36.3) (n=31)8.9 (13.0) (n=29)11.0 (27.4) (n=60)

covid-19=coronavirus disease 2019; HCQ=hydroxychloroquine; SOC=standard of care.

To convert values for creatinine to mg/dL, divide by 88.4. To convert values for total bilirubin to mg/dL, divide by 17.1.

  • * Weight in kilograms divided by square of height in metres.